-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AUGUST 25, 2020 /--- In a recent study, health scientists at the University of Utah and scientists at the National Institute of Allergy and Infectious Diseases (NIAID) developed an injectable drug that can stop HIV from entering cells.
the new drug has the potential to provide long-term protection against infection with fewer side effects.
. Michael S. Kay of american Medical Association University, senior author of the study, said, "This is a new approach to HIV prevention and treatment that has a unique mechanism of action compared to other approved drugs.
it has great potential to help patients with drug resistance.
the study was published in the journal PNAS.
(photo source: w) According to the World Health Organization, about 1.7 million people worldwide will be newly infected with HIV in 2019.
more than 38 million people are currently infected with the virus.
combination of antiretroviral therapy (cART), the so-called "drug cocktail", significantly improves the survival and quality of life of such patients, but it is also expensive and often has serious side effects.
addition, drug resistance has been a challenge because HIV often mutates, so researchers have been looking for new drugs with novel mechanisms to produce more effective combination therapies.
the new study, researchers tested a unique drug called CPT31, which targets key structures in the HIV fusion mechanism with few mutations.
CPT31 does not degrade in vivo.
, they have a longer service life than natural peptides and are therefore particularly suitable as long-acting injectable preparations.
, co-author of the study, said: "In addition to being persistent in the body, the drug is not attacked by the immune system, thus preventing autoimmune response."
we hope that CPT31 will provide extended viral suppression at lower doses and reduced side effects.
Bioon.com Source: Long-acting, injectable drug can strengthens to prevent, treat HIV Original source: Yoshiaki Nishimura et al Prevention, treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry, Proceedings of the National Academy of Sciences (2020). DOI: 10.1073/pnas.2009700117.
